{"id":"W2578812188","doi":"10.1016/j.jaip.2016.11.026","title":"Real-Life Outcomes for Patients with Asthma Prescribed Spacers for Use with Either Extrafine- or Fine-Particle Inhaled Corticosteroids","year":2017,"lang":"en","type":"article","venue":"The Journal of Allergy and Clinical Immunology In Practice","topic":"Inhalation and Respiratory Drug Delivery","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University","funders":"Efficacy and Mechanism Evaluation Programme; Medical Research Council; Genentech; National Institutes of Health; AstraZeneca; Chiesi Farmaceutici; Respiratory Effectiveness Group; Sunovion; Regeneron Pharmaceuticals; Teva Pharmaceutical Industries; National Heart, Lung, and Blood Institute; Pfizer; British Lung Foundation; Sanofi; Amgen; GlaxoSmithKline","keywords":"Medicine; Fluticasone propionate; Cohort; Asthma; Exacerbation; Rate ratio; Pediatrics; Inhalation; Fluticasone; Internal medicine; Cohort study; Anesthesia; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008165346,0.0003593281,0.0007545034,0.0004697331,0.0005125221,0.001248426,0.0004520699,0.001125352,0.002603064],"category_scores_gemma":[0.006186742,0.0001700447,0.00222266,0.0006362218,0.0003783882,0.001286976,0.0008845426,0.001760312,0.0004479664],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001120022,"about_ca_system_score_gemma":0.0005961029,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004097697,"about_ca_topic_score_gemma":0.004382447,"domain_scores_codex":[0.9992008,0.0002076908,0.000115106,0.0001467566,0.0001134986,0.0002162237],"domain_scores_gemma":[0.9957907,0.0008761815,0.001988897,0.0001299352,0.0003813274,0.0008330173],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002126303,0.0003291284,0.9910314,0.000111365,0.0005474049,0.0002019241,0.0001672446,0.0004026566,0.00008428824,0.0001035958,0.0006216507,0.004272968],"study_design_scores_gemma":[0.0001310953,0.002206628,0.9939165,0.00006908215,0.0004112687,0.0004858741,0.0008852792,0.0009274568,0.00007332734,0.0001982721,0.0006489306,0.00004633796],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960458,0.0007637417,0.00008093724,0.0003165462,0.00004025785,0.00002289959,0.001868819,0.000004688929,0.0008563062],"genre_scores_gemma":[0.9979487,0.0002281127,0.00005840132,0.0000759063,0.00003138184,0.00001581479,0.001466524,0.000002065357,0.000173066],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004097697,"threshold_uncertainty_score":0.00870806,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05393418058679038,"score_gpt":0.368722170770401,"score_spread":0.3147879901836106,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}